This is the authors' abstract. We don't add key points for this paper.
Co-infusion of ex-vivo generated megakaryocytic progenitors with hematopoietic stem/progenitor cells (HSC/HPC) may contribute to a faster platelet recovery upon umbilical cord blood (UCB) transplantation. A two stage protocol containing cell expansion and megakaryocyte (Mk) differentiation was established using human UCB CD34 + -enriched cells. The expansion stage used a pre-established protocol supported by a human bone marrow mesenchymal stem cells (MSC) feeder layer and the differentiation stage used TPO (100 ng/mL) and IL-3 (10 ng/mL). 18% of culture-derived Mks had higher DNA content (>4 N) and were able to produce platelet-like particles. The proliferation extent of CD34 + cells obtained in the expansion stage (FI-CD34 + ), rather than expansion duration, determined as a key parameter for efficient megakaryocytic differentiation. A maximum efficiency yield (EY) of 48 ± 7.7 Mks/input CD34 + cells was obtained for a FI-CD34 + of 17 ± 2.5, where a higher FI-CD34 + of 42 ± 13 resulted in a less efficient megakaryocytic differentiation (EY of 22 ± 6.7 and 19 ± 4.6 %CD41).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Hatami et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: